New injection aims to control rare bleeding disorder
NCT ID NCT07206758
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This early-stage study tests a new drug called SHR-2173 in 10 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The main goal is to see if the drug is safe and tolerable. Researchers will also check if it helps raise platelet counts over several weeks. This is not a cure; the drug aims to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact
Conditions
Explore the condition pages connected to this study.